Elisa Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 07-07-2024
- Paid Up Capital ₹ 2.50 M
as on 07-07-2024
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.14 Cr
as on 07-07-2024
- Revenue -9.20%
(FY 2023)
- Profit 22.91%
(FY 2023)
- Ebitda 13.79%
(FY 2023)
- Net Worth 22.94%
(FY 2023)
- Total Assets 3.84%
(FY 2023)
About Elisa Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.14 Cr.
Jyoti Nagpal, Mukesh Nagpal, and Reena Nagpal serve as directors at the Company.
- CIN/LLPIN
U24232DL2007PTC160045
- Company No.
160045
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Mar 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Elisa Biotech Private Limited offer?
Elisa Biotech Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Antihistamines, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Seeds and Plant Saplings, Oil Seeds, Cardiovascular Drugs & Medication.
Who are the key members and board of directors at Elisa Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyoti Nagpal  | Director | 27-Mar-2015 | Current |
| Mukesh Nagpal | Director | 02-Mar-2007 | Current |
| Reena Nagpal | Director | 18-Mar-2015 | Current |
Financial Performance of Elisa Biotech.
Elisa Biotech Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.2% decrease. The company also saw a substantial improvement in profitability, with a 22.91% increase in profit. The company's net worth Soared by an impressive increase of 22.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elisa Biotech?
In 2023, Elisa Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Oriental Bank Of Commerce Creation Date: 29 May 2009 | ₹1.40 M | Open |
Others Creation Date: 13 May 2009 | ₹1.00 Cr | Open |
How Many Employees Work at Elisa Biotech?
Unlock and access historical data on people associated with Elisa Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elisa Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elisa Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
